242 related articles for article (PubMed ID: 26256778)
1. Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
Song JY; Noh JY; Choi WS; Cheong HJ; Kim WJ
Expert Rev Anti Infect Ther; 2015; 13(11):1361-72. PubMed ID: 26256778
[TBL] [Abstract][Full Text] [Related]
2. [Current anti-influenza virus chemotherapy].
Yoshioka D; Tokimatsu I; Ishii H; Kadota J
Nihon Rinsho; 2010 Sep; 68(9):1679-84. PubMed ID: 20845747
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for H5N1: lessons learned from the H1N1 pandemic.
Reece PA
Postgrad Med; 2010 Sep; 122(5):134-41. PubMed ID: 20861597
[TBL] [Abstract][Full Text] [Related]
4. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV
J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200
[TBL] [Abstract][Full Text] [Related]
5. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
[TBL] [Abstract][Full Text] [Related]
6. Drugs: Lines of defence.
Palmer R
Nature; 2011 Dec; 480(7376):S9-10. PubMed ID: 22158299
[No Abstract] [Full Text] [Related]
7. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
8. Optimizing antiviral therapy for influenza: understanding the evidence.
Ison MG
Expert Rev Anti Infect Ther; 2015 Apr; 13(4):417-25. PubMed ID: 25695406
[TBL] [Abstract][Full Text] [Related]
9. The use of antiviral agents for the management of severe influenza.
Smith JR; Ariano RE; Toovey S
Crit Care Med; 2010 Apr; 38(4 Suppl):e43-51. PubMed ID: 19935416
[TBL] [Abstract][Full Text] [Related]
10. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
[TBL] [Abstract][Full Text] [Related]
11. Influenza viruses resistant to neuraminidase inhibitors.
Nitsch-Osuch A; Brydak LB
Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
[TBL] [Abstract][Full Text] [Related]
12. Therapy of H7N9 pneumonia: current perspectives.
Cao B; Hayden FG
Expert Rev Anti Infect Ther; 2013 Nov; 11(11):1123-6. PubMed ID: 24151830
[No Abstract] [Full Text] [Related]
13. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
[TBL] [Abstract][Full Text] [Related]
14. Developing new antiviral agents for influenza treatment: what does the future hold?
Hayden F
Clin Infect Dis; 2009 Jan; 48 Suppl 1():S3-13. PubMed ID: 19067613
[TBL] [Abstract][Full Text] [Related]
15. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Park S; Kim JI; Lee I; Lee S; Hwang MW; Bae JY; Heo J; Kim D; Jang SI; Kim H; Cheong HJ; Song JW; Song KJ; Baek LJ; Park MS
PLoS One; 2014; 9(7):e101325. PubMed ID: 24992479
[TBL] [Abstract][Full Text] [Related]
16. Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection.
Esposito S; Molteni CG; Colombo C; Daleno C; Daccò V; Lackenby A; Principi N
J Clin Virol; 2010 May; 48(1):62-5. PubMed ID: 20335065
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
18. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1.
Renaud C; Kuypers J; Englund JA
J Clin Virol; 2011 Oct; 52(2):70-8. PubMed ID: 21684202
[TBL] [Abstract][Full Text] [Related]
19. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Ikematsu H; Kawai N
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
[TBL] [Abstract][Full Text] [Related]
20. Influenza antiviral prescribing practices during the 2007-08 and 2008-09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses.
Dharan NJ; Beekmann SE; Fiore A; Finelli L; Uyeki TM; Polgreen PM; Fry AM
Antiviral Res; 2010 Nov; 88(2):182-6. PubMed ID: 20739002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
